A prospective, randomized, double blind, placebo-controlled evaluation of the effects of eicosapentaenoic acid and docosahexaenoic acid on the clinical signs and erythrocyte membrane polyunsaturated fatty acid concentrations in dogs with osteoarthritis

Stephen J. Mehler, Lauren R. May, Crystal King, William Harris, Zubin Shah

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Osteoarthritis (OA) in dogs is a prevalent and serious condition. The most common treatment for the clinical signs of OA in dogs is the administration of nonsteroidal antiiflammatory pharmaceuticals. Omega-3 (n-3) fatty acids have been shown to reduce the clinical signs of osteoarthritis in dogs. Objective: The primary goals of this study were 1) to determine the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on the clinical signs of OA in dogs, 2) to evaluate the effects of supplementation on the arachadonic acid (ARA)/ (EPA+DHA) algorithm and 3) to correlate alterations in the ARA/(EPA+DHA) with changes in the clinical signs of canine OA. Methods: Seventy-eight client owned dogs were enrolled in a prospective, randomized, double-blind, placebo controlled clinical trial. Dogs were randomized to placebo oil or triglyceride n-3 oil (providing an average dose of 69 mg EPA+DHA/kg/day). Orthopedic examinations and blood analyses were performed at baseline, day 42, and day 84. A single investigator confirmed a diagnosis of OA of the coxofemoral joints and/or stifle joints in all dogs. Results: Seventy-four dogs completed the trial. All clinical outcomes for measuring discomfort, lameness, and joint severity at day 84 and all blood metrics at day 42 and day 84 significantly (p

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalProstaglandins Leukotrienes and Essential Fatty Acids
Volume109
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Fingerprint

Eicosapentaenoic Acid
Docosahexaenoic Acids
Erythrocyte Membrane
Unsaturated Fatty Acids
Osteoarthritis
Placebos
Dogs
Membranes
Omega-3 Fatty Acids
Blood
Acids
Joints
Orthopedics
Oils
Triglycerides
Stifle
Controlled Clinical Trials
Pharmaceutical Preparations
Canidae
Research Personnel

Keywords

  • Alpha-linolenic acid
  • Arachidonic acid
  • Docosahexaenoic acid
  • Dogs
  • Eicosapentaenoic acid
  • Osteoarthritis
  • Polyunsaturated fatty acid

ASJC Scopus subject areas

  • Cell Biology
  • Clinical Biochemistry

Cite this

@article{413b0739e6bf4c97b75ff02da751557c,
title = "A prospective, randomized, double blind, placebo-controlled evaluation of the effects of eicosapentaenoic acid and docosahexaenoic acid on the clinical signs and erythrocyte membrane polyunsaturated fatty acid concentrations in dogs with osteoarthritis",
abstract = "Background: Osteoarthritis (OA) in dogs is a prevalent and serious condition. The most common treatment for the clinical signs of OA in dogs is the administration of nonsteroidal antiiflammatory pharmaceuticals. Omega-3 (n-3) fatty acids have been shown to reduce the clinical signs of osteoarthritis in dogs. Objective: The primary goals of this study were 1) to determine the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on the clinical signs of OA in dogs, 2) to evaluate the effects of supplementation on the arachadonic acid (ARA)/ (EPA+DHA) algorithm and 3) to correlate alterations in the ARA/(EPA+DHA) with changes in the clinical signs of canine OA. Methods: Seventy-eight client owned dogs were enrolled in a prospective, randomized, double-blind, placebo controlled clinical trial. Dogs were randomized to placebo oil or triglyceride n-3 oil (providing an average dose of 69 mg EPA+DHA/kg/day). Orthopedic examinations and blood analyses were performed at baseline, day 42, and day 84. A single investigator confirmed a diagnosis of OA of the coxofemoral joints and/or stifle joints in all dogs. Results: Seventy-four dogs completed the trial. All clinical outcomes for measuring discomfort, lameness, and joint severity at day 84 and all blood metrics at day 42 and day 84 significantly (p",
keywords = "Alpha-linolenic acid, Arachidonic acid, Docosahexaenoic acid, Dogs, Eicosapentaenoic acid, Osteoarthritis, Polyunsaturated fatty acid",
author = "Mehler, {Stephen J.} and May, {Lauren R.} and Crystal King and William Harris and Zubin Shah",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.plefa.2016.03.015",
language = "English (US)",
volume = "109",
pages = "1--7",
journal = "Prostaglandins Leukotrienes and Essential Fatty Acids",
issn = "0952-3278",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - A prospective, randomized, double blind, placebo-controlled evaluation of the effects of eicosapentaenoic acid and docosahexaenoic acid on the clinical signs and erythrocyte membrane polyunsaturated fatty acid concentrations in dogs with osteoarthritis

AU - Mehler, Stephen J.

AU - May, Lauren R.

AU - King, Crystal

AU - Harris, William

AU - Shah, Zubin

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background: Osteoarthritis (OA) in dogs is a prevalent and serious condition. The most common treatment for the clinical signs of OA in dogs is the administration of nonsteroidal antiiflammatory pharmaceuticals. Omega-3 (n-3) fatty acids have been shown to reduce the clinical signs of osteoarthritis in dogs. Objective: The primary goals of this study were 1) to determine the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on the clinical signs of OA in dogs, 2) to evaluate the effects of supplementation on the arachadonic acid (ARA)/ (EPA+DHA) algorithm and 3) to correlate alterations in the ARA/(EPA+DHA) with changes in the clinical signs of canine OA. Methods: Seventy-eight client owned dogs were enrolled in a prospective, randomized, double-blind, placebo controlled clinical trial. Dogs were randomized to placebo oil or triglyceride n-3 oil (providing an average dose of 69 mg EPA+DHA/kg/day). Orthopedic examinations and blood analyses were performed at baseline, day 42, and day 84. A single investigator confirmed a diagnosis of OA of the coxofemoral joints and/or stifle joints in all dogs. Results: Seventy-four dogs completed the trial. All clinical outcomes for measuring discomfort, lameness, and joint severity at day 84 and all blood metrics at day 42 and day 84 significantly (p

AB - Background: Osteoarthritis (OA) in dogs is a prevalent and serious condition. The most common treatment for the clinical signs of OA in dogs is the administration of nonsteroidal antiiflammatory pharmaceuticals. Omega-3 (n-3) fatty acids have been shown to reduce the clinical signs of osteoarthritis in dogs. Objective: The primary goals of this study were 1) to determine the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on the clinical signs of OA in dogs, 2) to evaluate the effects of supplementation on the arachadonic acid (ARA)/ (EPA+DHA) algorithm and 3) to correlate alterations in the ARA/(EPA+DHA) with changes in the clinical signs of canine OA. Methods: Seventy-eight client owned dogs were enrolled in a prospective, randomized, double-blind, placebo controlled clinical trial. Dogs were randomized to placebo oil or triglyceride n-3 oil (providing an average dose of 69 mg EPA+DHA/kg/day). Orthopedic examinations and blood analyses were performed at baseline, day 42, and day 84. A single investigator confirmed a diagnosis of OA of the coxofemoral joints and/or stifle joints in all dogs. Results: Seventy-four dogs completed the trial. All clinical outcomes for measuring discomfort, lameness, and joint severity at day 84 and all blood metrics at day 42 and day 84 significantly (p

KW - Alpha-linolenic acid

KW - Arachidonic acid

KW - Docosahexaenoic acid

KW - Dogs

KW - Eicosapentaenoic acid

KW - Osteoarthritis

KW - Polyunsaturated fatty acid

UR - http://www.scopus.com/inward/record.url?scp=84962136083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962136083&partnerID=8YFLogxK

U2 - 10.1016/j.plefa.2016.03.015

DO - 10.1016/j.plefa.2016.03.015

M3 - Article

C2 - 27269707

AN - SCOPUS:84962136083

VL - 109

SP - 1

EP - 7

JO - Prostaglandins Leukotrienes and Essential Fatty Acids

JF - Prostaglandins Leukotrienes and Essential Fatty Acids

SN - 0952-3278

ER -